StreetInsider.com News Articles

STAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026

Wed, 21 Oct 2026 16:01:00 -0400

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results and a letter to shareholders for the third quarter ended October 2, 2026, on Wednesday, November 4, 2026, after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET that same day to discuss its financial results and business progress.

Event: STAAR Surgical Third Quarter 2026 Financial Results Webcast
Date: Wednesday, November 4, 2026
Time:

STAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026

Wed, 21 Oct 2026 16:01:00 -0400

Event: STAAR Surgical Third Quarter 2026 Financial Results Webcast
Date: Wednesday, November 4, 2026
Time:

Staar Surgical appoints Andrew Pilon as VP of business development

Thu, 08 Oct 2026 15:14:15 -0400

Staar Surgical Company (NASDAQ: STAA) has appointed Andrew Pilon, O.D., as Vice President of Business Development, according to a company press release. Dr. Pilon will report to President and Chief Executive Officer Warren Foust.

Dr. Pilon joins Staar from Johnson & Johnson Vision, where he spent nearly six years as Senior Director of Business Development for the Surgical Vision division. In that role, he led efforts to evaluate and advance strategic partnerships, acquisitions, and licensing opportunities across Johnson & Johnson's global ophthalmology portfolio. He previously served as Johnson & Johnson's Senior Director of New Ventures & Transactions for Vision Science.

Before Johnson

STAAR Surgical Names Andrew Pilon as Vice President of Business Development

Thu, 08 Oct 2026 15:14:00 -0400

Accomplished Ophthalmic Industry Executive and Clinician to Help Advance STAAR’s Strategic Partnerships, Innovation Opportunities, and Multi-Product Platform Strategy

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon will report to STAAR President and Chief Executive Officer Warren Foust and will work closely with the Company’s senior leadership team to capitalize on opportunities that support STAAR’s innovation strategy and

STAAR Surgical Names Andrew Pilon as Vice President of Business Development

Thu, 08 Oct 2026 15:14:00 -0400

Accomplished Ophthalmic Industry Executive and Clinician to Help Advance STAAR’s Strategic Partnerships, Innovation Opportunities, and Multi-Product Platform Strategy

Form 8-K/A STAAR SURGICAL CO For: Sep 08

Mon, 05 Oct 2026 12:25:00 -0400

si-local-file:///var/storage/secattach/20261005/27147766.html

STAAR Surgical jumps on Stifel upgrade citing China growth potential

Tue, 29 Sep 2026 10:12:30 -0400

Investing.com -- STAAR Surgical Company (NASDAQ:STAA) shares rallied 7% in early Tuesday trade following an upgrade from Stifel, which pointed to improving international sales momentum and favorable product mix trends. Analyst Thomas Stephan raised Stifel's rating on the ophthalmic medical device manufacturer to Buy from Hold while lifting its price target to $31 from $28.

The upgrade reflects growing confidence in the company's second-half trajectory for 2026, supported by an accelerating shift toward higher-margin products in China. Meanwhile, easing year-over-year comparisons across markets outside China are expected to provide additional tailwinds for global

STAAR Surgical jumps on Stifel upgrade citing China growth potential

Tue, 29 Sep 2026 10:12:30 -0400

Stifel Upgrades STAAR Surgical (STAA) to Buy

Tue, 29 Sep 2026 02:07:06 -0400

Stifel analyst Thomas M. Stephan upgraded STAAR Surgical (NASDAQ: STAA) from Hold to Buy with a price target of $31.00 (from $28.00).

The analyst comments: “We are upgrading STAA from Hold to Buy. 2H26 Upside: We see a path to 2H26 sales upside, aided by both China (EVO+ mix shift-driven) and ex-China (easing comps).

2027 Upside: Mix shift toward the higher-ASP EVO+ can be a meaningful source of 2027 China revenue growth—when coupled with the lapping of Middle East headwinds, 2027 revenue upside also appears likely.

2028 Bull/Base/Bear Scenario Analysis: Our comprehensive 2028 bull/base/bear revenue scenario analysis yields a base case 2026-2028

Stifel Upgrades STAAR Surgical (STAA) to Buy

Tue, 29 Sep 2026 02:07:06 -0400

Stifel analyst Thomas M. Stephan upgraded STAAR Surgical (NASDAQ: STAA) from Hold to Buy with a price target of $31.00 (from $28.00).

The analyst comments: “We are upgrading STAA from Hold to Buy. 2H26 Upside: We see a path to 2H26 sales upside, aided by both China (EVO+ mix shift-driven) and ex-China (easing comps).

2028 Bull/Base/Bear Scenario Analysis: Our comprehensive 2028 bull/base/bear revenue scenario analysis yields a base case 2026-2028

STAAR Surgical stock ticks higher on $50M buyback authorization

Thu, 24 Sep 2026 16:39:04 -0400

Investing.com -- STAAR Surgical Company (NASDAQ:STAA) shares rose as much as 2% in after-hours trading Thursday following the company's announcement of a $50 million share repurchase program authorized by its Board of Directors.

The medical device company, which specializes in phakic intraocular lenses for vision correction, said it may repurchase shares through open market transactions, privately negotiated deals, structured repurchase agreements, block purchases, or Rule 10b5-1 trading plans. The program is expected to continue over the next twelve months, though it may be modified, suspended, or discontinued at any time.

STAAR Surgical Company (NASDAQ:STAA) shares rose as much as 2% in after-hours trading Thursday following the company's announcement of a $50 million share repurchase program authorized by its Board of Directors.

Shows 80% of Consumers Want to be Free of Glasses and Contacts, 58% Want a Reversible Option, and 59% Are Opposed to Laser Correction

Safety Concerns and Procedure Fears Outrank Affordability as Primary Barriers to Laser Correction

Consumer Research Uncovers the Demand Drivers Fueling Implantable Lens Growth as Laser Procedures Stagnate or Decline in Markets Surveyed

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today released a new report entitled The Future of

STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction

Thu, 10 Sep 2026 07:00:00 -0400

Shows 80% of Consumers Want to be Free of Glasses and Contacts, 58% Want a Reversible Option, and 59% Are Opposed to Laser Correction
Safety Concerns and Procedure Fears Outrank Affordability as Primary Barriers to Laser Correction
Consumer Research Uncovers the Demand Drivers Fueling Implantable Lens Growth as Laser Procedures Stagnate or Decline in Markets Surveyed

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today released a new report entitled The Future of

Form 8-K STAAR SURGICAL CO For: Sep 09

Thu, 10 Sep 2026 06:00:00 -0400
si-local-file:///var/storage/secattach/20260910/27044490.html

Form 4 STAAR SURGICAL CO For: Aug 14 Filed by: Michna Magda

Tue, 18 Aug 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260818/26944098.html

Form 4 STAAR SURGICAL CO For: Aug 14 Filed by: Michna Magda

Tue, 18 Aug 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260818/26944098.html

Form 4 STAAR SURGICAL CO For: Aug 14 Filed by: ANDREWS DEBORAH J

Tue, 18 Aug 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260818/26944095.html

Form 4 STAAR SURGICAL CO For: Aug 14 Filed by: ANDREWS DEBORAH J

Tue, 18 Aug 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260818/26944095.html

Form 4 STAAR SURGICAL CO For: Aug 14 Filed by: Foust Warren

Tue, 18 Aug 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260818/26944094.html

Form 4 STAAR SURGICAL CO For: Aug 14 Filed by: Foust Warren

Tue, 18 Aug 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260818/26944094.html

STAAR Surgical (STAA) PT Lowered to $28 at Stifel After Net-Positive Earnings Call

Mon, 17 Aug 2026 07:02:08 -0400

Stifel analyst Thomas M. Stephan lowered the price target on STAAR Surgical (NASDAQ: STAA) to $28.00 (from $31.00) while maintaining a Hold rating.
The analyst commented, "The updates from the earnings call (which follow the mid-July pre-announcement) were net-positive, in our view—highlighted by China share gains, encouraging China trends (contrary to cautious commentary from competitors), EVO+ momentum, and solid EBITDA. Importantly, the company appears comfortable with Street’s low-$80M 3Q26 revenue estimate and ~$335M FY26 figure—although the lack of formal guidance may continue to frustrate investors and add to uncertainty about how “real” the China rebound is. The 2H26 setup appears positive,